Inspire touts coverage win

 - 
Tuesday, August 27, 2019

MINNEAPOLIS – Two Medicare Administrative Contractors, Noridian and Palmetto, have published draft local coverage determinations that propose coverage for Inspire Medical Systems’ obstructive sleep apnea therapy, according to the company. Both draft LCDs state that for individuals with OSA who are treated with hypoglossal nerve stimulation, the evidence is sufficient to determine that neurostimulation technology results in a meaningful improvement in the net health outcomes when used as outlined. “This is a very positive advancement for the Medicare-aged population that has the potential to streamline their access to Inspire therapy,” said Tim Herbert, president and CEO. “We look forward to the formal policies from Noridian and Palmetto, and anticipate that other MACs will also soon issue their draft policies.” The LCDs are in a public comment period for 60 days, then will move to formal review by Noridian in September and by Palmetto in October. The company expects the MACs to issue final policies in 2020.